Treatment with AXS-05, a combination of dextromethorphan （medicon) and bupropion, demonstrated rapid, sustained, and clinically meaningful improvement in agitation related to Alzheimer's disease (AD) and was generally well tolerated in the phase 3 ACCORD trial.
